Characterizing a rat Brca2 knockout model.

Authors: Cotroneo, MS  Haag, JD  Zan, Y  Lopez, CC  Thuwajit, P  Petukhova, GV  Camerini-Otero, RD  Gendron-Fitzpatrick, A  Griep, AE  Murphy, CJ  Dubielzig, RR  Gould, MN 
Citation: Cotroneo MS, etal., Oncogene. 2006 Sep 11;.
Pubmed: (View Article at PubMed) PMID:16964288
DOI: Full-text: DOI:10.1038/sj.onc.1209960

Evidence exists that BRCA2 carriers may have an elevated risk of breast, ovarian, colon, prostate, and pancreatic cancer. In general, carriers are defined as individuals with protein truncating mutations within the BRCA2 gene. Many Brca2 knockout lines have been produced and characterized in the mouse. We previously produced a rat Brca2 knockout strain in which there is a nonsense mutation in exon 11 between BRC repeats 2 and 3, and a truncated protein is produced. Interestingly, while such a mutation in homozygous mice would lead to limited survival of approximately 3 months, the Brca2(-/-) rats are 100% viable and the vast majority live to over 1 year of age. Brca2(-/-) rats show a phenotype of growth inhibition and sterility in both sexes. Aspermatogenesis in the Brca2(-/-) rats is due to a failure of homologous chromosome synapsis. Long-term phenotypes include underdeveloped mammary glands, cataract formation and lifespan shortening due to the development of tumors and cancers in multiple organs. The establishment of the rat Brca2 knockout model provides a means to study the role of Brca2 in increasing cancer susceptibility and inducing a novel ocular phenotype not previously associated with this gene.Oncogene advance online publication, 11 September 2006; doi:10.1038/sj.onc.1209960.

Annotation

Disease Annotations
Gene Ontology Annotations
Phenotype Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 1599505
Created: 2007-02-06
Species: All species
Last Modified: 2007-02-06
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.